Pfizer Inc is in talks to merge its off-patent drugs business with Mylan NV in a...
) in a stock deal, the Wall Street Journal reported on Saturday, citing people familiar with the matter.
Mylan shareholders would receive a little more than 40% of the newly formed entity, with Pfizer shareholders receiving the remainder, the Journal said, adding Pfizer would also get about $12 billion in proceeds from a new sale of debt.Reporting by Maria Ponnezhath in Bengaluru; Editing by Mark Potter
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Pfizer Nears Deal to Combine off-Patent Drug Business With MylanPfizer is in talks to merge its off-patent drugs business with generic drugmaker Mylan, in a deal that would create a giant global seller of lower-priced medicines.
Leer más »
FDA Requires Box Warnings for Pfizer Drug XeljanzThe U.S. Food and Drug Administration is requiring that health warnings be added to Pfizer Inc.’s drug Xeljanz, advising patients they could experience a higher risk of blood clots or death with a specific dose.
Leer más »
Pfizer Nears Deal to Combine off-Patent Drug Business With MylanPfizer is in talks to merge its off-patent drugs business with generic drugmaker Mylan, in a deal that would create a giant global seller of lower-priced medicines.
Leer más »
FDA Requires Box Warnings for Pfizer Drug XeljanzThe U.S. Food and Drug Administration is requiring that health warnings be added to Pfizer Inc.’s drug Xeljanz, advising patients they could experience a higher risk of blood clots or death with a specific dose.
Leer más »
The Tiny Drug Dealer Kid From 'Euphoria' Has the Best Instagram You've Ever SeenNot to be dramatic, but I would die for Ashtray.
Leer más »
There's no business like the arms business: Here's how the top US defense companies did in Q2 earningsNobody spends money on arms like the United States, and it shows in the bottom lines of the biggest defense contractors.
Leer más »